Intra-Cellular’s schizophrenia drug Calypta has recently gained FDA approval for bipolar depression. In response, the company has launched a aggressive new direct-to-customer (DTC) ad campaign for the newly-added indication. In April alone, Intra-cellular has spent over $13 million marketing the drug. Unlike many drugs for the disorder, Calypta is indicated for bipolar I and bipolar II.
According to Ben Adams of Fierce Pharma,” The two varieties of bipolar disorder affect around 11 million adults in the U.S. and are characterized by recurring episodes of mania (highs) interposed with episodes of major depression. Bipolar I and bipolar II, which is milder, each account for half of people with bipolar disorder.”
To read more, click here.
(Source: Fierce Pharma, May 9th, 2022)